Related Experiment Video

Updated: Jun 29, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

[Imatinib induces c-kit positive myeloma cells apoptosis]

Juan Li1, Bei-Hui Huang, Ying Zhao

  • 1Department Hematology of the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.

Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|October 11, 2008
PubMed
Abstract

Insights

Imatinib effectively inhibits multiple myeloma cell proliferation and induces apoptosis by targeting c-kit signaling. This study demonstrates Imatinib

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Multiple myeloma is a cancer of plasma cells.
  • c-kit is a receptor tyrosine kinase implicated in various cancers.
  • Imatinib is a tyrosine kinase inhibitor.

Purpose:

  • To investigate the in vitro effects of Imatinib on multiple myeloma cells expressing c-kit.
  • To elucidate the underlying mechanisms of Imatinib's action.

Summary:

  • Imatinib demonstrated dose-dependent inhibition of KM3 multiple myeloma cell proliferation with an IC50 of 0.33 micromol/L.
  • Imatinib induced G0/G1 cell cycle arrest and apoptosis, evidenced by Annexin V/PI staining and DNA ladder assays.
  • The drug reduced c-kit expression and inhibited IL-6-induced c-kit phosphorylation, suggesting c-kit signaling pathway inhibition.

Impact:

  • Imatinib exhibits therapeutic potential against c-kit expressing multiple myeloma.
  • The findings provide mechanistic insights into Imatinib's anti-myeloma activity.
  • This research may inform the development of targeted therapies for multiple myeloma.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...